How Moderna's melanoma mRNA vaccine could fight deadliest skin cancer

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines against cancer."

The vaccine is built on the mRNA platform that allowed Moderna to quickly roll out COVID-19 vaccines five years ago.

Moderna Stock Soars on Cancer Vaccine Success  WSJ

Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran autogene, met its endpoints in a phase 3 trial in melanoma patients. It is the first positive result at that stage for an mRNA-based cancer treat

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.

The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells

Drugmaker’s melanoma shot developed with Merck delivers positive outcome in late-stage trial

Moderna shares jump 175% on skin cancer trial success  The Times

Pharmaceutical companies Moderna and Merck announced today the highly promising results of their anti-cancer mRNA vaccine Phase 3 clinical trial targeting later-stage melanoma skin cancers. Researchers sequenced the DNA from each patient's tumors to create personalized vaccines that, when injected, rev up the immune sy

The results mark a step forward in the effort to treat not just melanoma but other forms of cancer with vaccines designed to help keep patients disease-free.

Moderna vaccine cuts recurrence and spread of high-risk melanoma, raising new treatment hope  Reuters

Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial.  The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically removed. In early results